|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.6500 - 0.6720|
|52 Week Range||0.5140 - 2.0300|
|Beta (3Y Monthly)||4.19|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Vancouver, BC, March 15, 2019 -- INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA: 8IS1) is pleased to announce the appointment of.
FRA: 8IS1) is pleased to provide an update on its binding letter of intent to create a joint venture with Cannamerica Brands Corp. (CSE:CANA) (CNNXF) and CBDistribution Company Ltd. (collectively, the “Joint Venture”) that was previously announced on January 7, 2019, with the intention of acquiring hemp biomass for extraction into CBD isolate using purpose-built facilities for large scale CBD extraction. The transaction is anticipated to close on or before March 31, 2019. Each of the parties involved have received approval from their respective Board of Directors to enter into the Joint Venture.
FRA: 8IS1) is pleased to provide an update on production and expansion plans at its Licensed Producers: Acreage Pharms Ltd. (“Acreage Pharms”), AB Laboratories Inc. (“AB Labs”) and 0989561 B.C. Ltd. ("Canandia"). Invictus is proud to have fulfilled 100 per cent of provincial product orders to date and looks to further strengthen its sales and distribution relationships with both public and private enterprises as the Company’s facilities reach full operating capacity. A production footprint of 189,000 square feet is underway, with more capacity to come online commensurate with market needs and funding.
Industry participants believe the cannabis segment will become a $500 billion industry. For now, it is a fraction of that potential. There have been some companies that have seen significant movements in their stock prices. What I wanted to do is point out some lesser-known stocks that still have the potential for large movements in their stocks. These stocks have lower volumes and are prone to bigger swings as these companies ramp up production. If an investor could stomach a wild ride there may be long-term potential with these companies.1933 Industries1933 Industries (TGIFF) is a Canadian company whose market capitalization is just under $100 million. They are taking steps almost daily to grow their business including getting involved in Canadian adult-use cannabis sales. Currently, the company operates in Nevada with retail and grow operations (although they have a presence in other states such as California and Colorado). This company has potential as they are just on the cusp of profitability with their increasing revenue and their declining rate of net losses. And, their stock is just starting to pick back up after its selloff from initial euphoria:If you want a detailed look at the company’s growth they have a large flow chart of their progression to date. I am still waiting to hear back from the company regarding their total production capabilities. But, if you scan through the flow chart they provide my best guess is close to 50,000 kg of cannabis annually. This puts the company at a potential valuation based on their production possibility and revenue potential. I’m looking at a bigger picture with this company and think they have the ability to accelerate their earnings in short order.Invictus MDInvictus MD (IVITF) is about to up-list on the NASDAQ and that is good news for the stock. The increased exposure on more mainstream markets will bring in higher volumes and tighter spreads reducing investor risk. But, the real draw for me was the fact that within 18 months the company will be producing some 50,000 kg of cannabis annually. With that kind of potential, this company could be nearly $1 billion valuation in about 20 months’ time as the company ramps up production. However, the company’s current valuation is still below $100 million giving the potential of a 10-times price movement.Given these two variables, I like this company a great deal. Also, their stock price is at a basic price of $0.74 per share allowing for ownership of large numbers. I will be constantly monitoring the company as I look for new information on what is next for this company:AgraFloraFrom what I can tell, AgraFlora (PUFXF) is a perfect example of a company who’s stock is mis-priced. First, the company has teamed up with a long-term tomato grower that has many years of experience with indoor growing facilities, HVAC, and controlled indoor grow environments for vegetables. There is not a tremendous amount of difference in the grow process of one plant versus another. So, the company’s partner may be the best yet in the industry. AgraFlora will have 250,000 kg annual production facility up and running very shortly. Plus, the partnership they have will ensure viability with getting their business up and running as they switch from tomatoes to cannabis.With 250,000 kg. of cannabis production capability, that could eventually value the company at $5 billion. They are currently valued at under $100 million. Their stock has been pushed downward but that may be a factor of the low volumes for the stock. But, long-term, I see a tremendous amount of potential; this stock may become my favorite for a while:Check out the articles in this category focused on cannabis stocks. By gaining a strong foundation in both the fundamentals and technical details usually involved in cannabis stocks, you’ll be able to invest with greater confidence. Author’s Disclosure: I have no positions on these stocks at this time nor will be placing trades on these stocks in the next 72 hours. More recent articles from Smarter Analyst: * Last Minute Thought: Buy or Sell Micron (MU) Stock Before 2Q19 Report? * Apple (AAPL): iMac Update Should Not Affect the Stock Negatively -- Here's Why * There’s a Lot to Like About AMD Stock, But Don't Buy Into the Google Hype * A Big Week for Cannabis Stocks as Tilray (TLRY) Posted 110% Revenue Growth
FRA: 8IS1) is pleased to announce that its wholly-owned subsidiary, Acreage Pharms Ltd. ("Acreage Pharms"), has successfully completed testing on two batches of oil and is working to finalize its application to Health Canada to allow for the sale of bottled cannabis oil and cannabis resin. Acreage Pharms' closed-loop CO2 system performs Subcritical and Supercritical Fluid Extraction utilizing high-pressure carbon dioxide to extract essential oils from botanicals, using specific temperatures and pressures to withdraw different components from plants.
FRA: 8IS1) is pleased to announce that its wholly-owned subsidiary, Acreage Pharms Ltd. ("Acreage Pharms"), has signed an agreement to supply the Ontario Cannabis Retail Corporation (“OCRC”), through the Ontario Cannabis Store (“OCS”), with a selection of premium cannabis products for the adult recreational market. Acreage Pharms, located in Edson, Alberta, is Invictus’ largest purpose-built indoor facility fully licensed under the Cannabis Act and Cannabis Regulations.
With over 35 years of branding experience in the healthcare sector, the Agency will leverage its expertise to help create, develop, and execute the go-to-market strategy for Invictus cannabis products. As interim CMO, the Agency will work with Authentic Brands Group (“ABG”) and Invictus’ senior leadership team to facilitate the anticipated launch of Invictus’ medical brand T2C, and adult recreational brands under Dukes and Sterling & Hunt.
The past several months have been incredible ones for marijuana stocks. Although many of them have been around for years, nationwide legalization in Canada and legalization progress in the United States has thrust a large handful of cannabis stocks like Canopy Growth (NYSE:CGC), Aurora Cannabis (NYSE:ACB) and Tilray (NASDAQ:TLRY) in the spotlight. It has also pushed most of these stocks much higher. Click to Enlarge Source: Shutterstock The sheer speed and scope prompts a huge question most investors have avoided asking, however -- are marijuana stock overvalued?They are.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThere's more to the answer than just the acknowledgment though. Namely, being overvalued isn't the same thing as calling these companies a sham. It also doesn't preclude gains in the meantime that will make them even more overvalued, even beyond typical measures of value like price-to-earnings ratios or cash flow potential. It's not unfair to "value" this industry's players solely based on the premise for the time being.Nevertheless, at some point in time these organizations will have to justify their stunningly frothy prices. Once the market realizes they can't, that's when the wave of right-pricing begins. Experts Sound OffIt's undeniable that the pro-cannabis movement is gaining traction. Canada is completely on board, even if its retail choices are modest. Meanwhile, marijuana is now legal for one reason or another in ten U.S. states. The light at the end of the tunnel has set most marijuana stocks on fire, and for good reason. Not only does legalization represent more opportunity, it has made them potential acquisition targets. * 10 Stocks That Every 20-Year-Old Should Buy That doesn't mean investors have remained rational about the whole premise though.Consider something Canopy Growth CEO Bruce Linton said just late last week:"I think it's entirely true that cannabis has become frothy and I'm not saying that necessarily specifically about our [stock]. But you could list 85 or 90 names that are probably publicly listed that I as the operator of one of the first and most dominant [companies] have never heard of those companies."Again, that's from Bruce Linton, chief of Canopy Growth, and someone who has much to gain by not suggesting anything close to what he said.Linton isn't the only insider or industry expert to point out concern, however, that early pot investors have gotten ahead of themselves. Bethany Gomez, managing director at Brightfield Group, commented in a recent interview:"Another full third of consumers who are not purchasing through the retail market yet have cited pricing as one of their key concerns … that pricing differential between the recreational market and the black market … the market is really missing those mid to lower income cannabis consumers which are a significant portion of that population."In other words, a good-sized swath of would-be tokers -- and suppliers -- are still circumventing the legalized arm of the industry. Investors were pricing marijuana stocks as if the illegal side of the trade would shift to legal operations. One can't invest in the unregulated, illegal swath of the marijuana business that clearly still exists, and still competes with publicly traded outfits in the cannabis industry.Jon Najarian, co-founder of Investitute, was a little more blunt about the matter in September of last year, commenting on the wild runup of most marijuana stocks "This is just stupid time. I can't believe the valuations at this stage."Little has changed, valuation-wise, since then. All the Telltale SignsEven beyond the expert opinions though, the ancillary evidence of froth among these stocks is in place.No two bubbles are quite the same, but they all eventually sport the same core warning signs that are in place now. One of those warning signs in place now is, everyone and their uncle is talking about investing in marijuana … including people who've never actually invested a penny in their lives.And they're not just talking about it. They're adamant about it, to the point of being critical of those who are "missing out" on the movement. It's mostly an effort to assure themselves they made the right call.Another red flag? The industry's focus has shifted from doing the business to supporting those who want to get in the business to raising awareness -- and raising funds -- by merely name-dropping or leveraging celebrities' star power. Most notable among such moves is the naming of Gene Simmons, the face and lead singer of rock band Kiss, as the Chief Evangelist Officer of Invictus MD Strategies (OTCMKTS:IVITF). The company's Canadian ticker was even changed to 'GENE' to bolster the affiliation.It's a title fabricated solely for publicity purposes, with a role filled by a talented showman with no particularly related work experience.Lastly, the mindset keeping these names propped up, for the time being, is the same one that sent solar stocks soaring in 2008, oil stocks into a rocket-ride into 2014, gold in a frenzy in 2010 and 2011, bitcoin into a mania in 2017 and 3D printing stocks into high gear in 2012 and 2013. Those were all "must have" investments at the time, as they would change the world as we knew it. * 7 Forever Stocks to Buy for Long-Term Gains They didn't. The underlying stories sure were fun to think about though. Bottom Line for Marijuana StocksThe great irony (and frustration) is, cannabis is a real, viable industry. Some observers believe the global legal marijuana market could be worth nearly $150 billion by 2025. Even half of that figure would still be an incredible opportunity.It's short-sighted, however, to believe the market's most-talked-about marijuana stocks are going to hold onto their present prices between now and then. Much can happen within the next five years that sheds the light of reality on these hyped-up names, not the least of which is the plethora of privately held companies that could end up outgrowing outfits like Tilray and Canopy Growth by avoiding all the trappings of being publicly traded entities.It certainly doesn't mean certain cannabis stocks won't see more short-term forward progress again, in the near or distant future. A bubble has made marijuana stocks sharply overvalued in terms of risk, potential and how compelling their stories are though … even if few want to admit it.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Fundamentally Sound Dividend Stocks to Buy * 5 Reasons Reeling FAANG Stocks Won't Deliver Big Returns * 3 Reasons Canopy Growth Could Burn You Compare Brokers The post Are Marijuana Stocks Generally Overvalued? appeared first on InvestorPlace.
Investorideas.com, a leading investor news resource covering hemp and cannabis stocks, releases a snapshot focused on the CBD edibles market and how, specifically, CBD gummies are in high demand. Building on that, Transparency Market Research expects the global market for gummy vitamins to rise at a steady CAGR of 5.2% during the period between 2017 and 2025. Last November, Canopy Growth Corporation (NYSE:CGC) (TSX:WEED.TO) started selling CBD-dominant softgels through its Tweed brand, containing 20 milligrams of CBD, and between 2.5 or 10 milligrams of THC.
FRA: 8IS1) is pleased to provide an update on its binding letter of intent ("LOI") to create a joint venture with Cannamerica Brands Corp. ("CannAmerica") (CSE:CANA) (CNNXF) and CBDistribution Company Ltd. ("CBDC") (collectively the "Joint Venture") that was previously announced on January 7, 2019 with the intention of acquiring hemp biomass for extraction into CBD isolate using purpose-built facilities for large scale CBD extraction. Invictus is pleased to announce that it has received approval from its Board of Directors to enter into the Joint Venture with CannAmerica and CBDC.
FRA: 8IS1) announced today an update to its intention to proceed with a consolidation of its issued and outstanding shares with a newly proposed reduced share consolidation ratio of one new share for every five old shares (1:5) in connection with its proposed listing on Nasdaq Stock Market LLC ("Nasdaq"). The purpose of the consolidation is to increase the Company's common share price to be in compliance with Nasdaq's minimum share price listing requirement of USD $3.00 (CAD $3.98 ).
VANCOUVER , Jan. 21, 2019 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA: 8IS1) is pleased to announce that the Company's ...
VANCOUVER , Jan. 17, 2019 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA: 8IS1) is pleased to announce that George E. Kveton, ...
FRA: 8IS1) is pleased to announce that it has submitted its application to list its common shares (the "Shares") on the NASDAQ Capital Market ("NASDAQ"). In advance of listing on NASDAQ, the Company will file a Form 40-F Registration Statement with the United States Securities and Exchange Commission.
FRA: 8IS1) is pleased to provide an update on its binding letter of intent ("LOI") to create a joint venture with Cannamerica Brands Corp. ("CannAmerica") (CSE:CANA) (CNNXF) and CBDistribution Company Ltd. ("CBDC") (collectively the "Joint Venture") that was previously announced on January 7, 2019 with the intention of acquiring hemp biomass for extraction into CBD isolate using purpose-built facilities for large scale CBD extraction. The Joint Venture has entered into a binding LOI with Z3 Sciences, LLC ("Z3") to purchase 80% of the membership interests of Z3 for aggregate consideration, including performance incentives, of USD$42.25 million. Z3 is expected to provide the Joint Venture with existing extraction contracts from extracting Hemp biomass into CBD isolate.
Invictus And GTEC Holdings Announce Formal Termination of Merger Plans and Maintain Existing Working Relationship
VANCOUVER , Jan. 15, 2019 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA: 8IS1) is pleased to announce that the Company's Board ...